Updated:
Organigram Global
Organigram is a global leader in cannabis, renowned for its innovation, quality, and trusted portfolio of brands. It redefines the cannabis industry through...
Organigram Global
Organigram is a global leader in cannabis, renowned for its innovation, quality, and trusted portfolio of brands. It redefines the cannabis industry through innovation, beloved consumer brands, and a growing international presence. The company pushes boundaries in cultivation and product development using a scientific approach and cutting-edge technology, and strategically invests in and partners with companies to extend its reach beyond Canada.
General information
Firm type
Asset Manager
Location
Region
North America
Country
Canada
City
Toronto
Corporate office
Toronto, ON, Canada
Additional offices
Moncton, NB · Lac-Supérieur, QC · Winnipeg, MB · Aylmer, ON · London, ON
Principals
James Yamanaka
Chief Executive Officer
Beena Goldenberg
Chief Executive Officer
Greg Guyatt
Chief Financial Officer
Tim Emberg
President of Organigram Canada
Paolo de Luca
Chief Strategy Officer
Helen Martin
Chief Legal Officer
Valerie Rother
Chief People Officer
Megan McCrae
Senior VP of Corporate Strategy & International Growth
Borna Zlamalik
Senior VP of Innovation and International R&D
Bradley Gunter
Senior VP of Sales
Steven Nazarian
Senior VP of Innovation and Product Development Engineering
Geoffrey Machum
Director
Sector focus
Frequently asked questions
How is Organigram structured as a corporate entity?
Organigram Global Inc. is a publicly traded company listed on the Toronto Stock Exchange, not a family office or private holding vehicle. It operates as a vertically integrated cannabis consumer packaged goods company, cultivating, extracting, manufacturing, and distributing branded products across Canada and through international supply agreements.
Which sectors does Organigram Global explicitly focus on?
The firm concentrates entirely on regulated cannabis, covering flower, pre-rolls, edibles, vapes, extracts, and lozenges. Its portfolio includes value brands like SHRED, premium lines like Edison, and wellness-oriented products like Monjour. It does not operate outside cannabis or adjacent into broader consumer goods.
Does Organigram Global participate in fund commitments or only direct operating investments?
Organigram invests directly in wholly owned operating subsidiaries and brands, not as a limited partner in external funds. Its corporate development strategy relies on acquisitions like the 2024 Motif Labs deal and structured international partnerships, rather than passive fund commitments or venture-style minority positions.
What is Organigram's known posture on co-investments alongside external companies?
Organigram enters structured strategic agreements rather than blind-pool co-investment arrangements. Its 2023 agreements with Sanity Group, 4C Labs, and Phylos Bioscience are supply, licensing, and intellectual property partnerships, not co-investment vehicles. Each deal includes defined commercial terms for product distribution in specific non-Canadian jurisdictions.
Where does Organigram's revenue come from geographically?
The firm's primary revenue engine is the Canadian adult-use market, served by its cultivation, extraction, and manufacturing facilities in New Brunswick, Quebec, Manitoba, and Ontario. International revenue channels are developing through its German and UK agreements, but the company has not disclosed the percentage of total revenue from non-Canadian sources.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: